Journal of Pediatric Pharmacology and Therapeutics最新文献_第6页

The Potential Application of Large Language Models in Pharmaceutical Supply Chain Management. 大型语言模型在医药供应链管理中的潜在应用。

Journal of Pediatric Pharmacology and Therapeutics Pub Date : 2024-04-01 Epub Date: 2024-04-08 DOI: 10.5863/1551-6776-29.2.200

David Aguero, Scott D Nelson

引用次数: 0

Evaluation of KIDs List Compliance at a Children's Hospital Within a Large Academic Medical Center. 大型学术医疗中心内一家儿童医院的 KID 列表合规性评估。

Journal of Pediatric Pharmacology and Therapeutics Pub Date : 2024-01-01 Epub Date: 2024-02-07 DOI: 10.5863/1551-6776-29.1.61

Alexandra Cooper, Shannon Lyons, Lisa Thames, Timothea Scott, Ansley Gayle, Alexandra Lehman, Tara Higgins

{"title":"Evaluation of KIDs List Compliance at a Children's Hospital Within a Large Academic Medical Center.","authors":"Alexandra Cooper, Shannon Lyons, Lisa Thames, Timothea Scott, Ansley Gayle, Alexandra Lehman, Tara Higgins","doi":"10.5863/1551-6776-29.1.61","DOIUrl":"10.5863/1551-6776-29.1.61","url":null,"abstract":"Objectives: In 2020, a list of Key Potentially Inappropriate Drugs in Pediatrics, known as the \"KIDs List,\" was published. The objective of this analysis was to evaluate institutional compliance with the -recommendations in this publication and identify areas for improvement.Methods: Medications in the KIDs List were compared to the institutional formulary at a large academic medical center caring for pediatric and adult patients. Medications listed in the formulary were then -evaluated for order comments and restrictions related to their use in pediatric patients. Oral liquid products and a group of commonly used intravenous (IV) medications were reviewed for potentially inappropriate excipients through available manufacturer information. The pediatric clinical specialists were then solicited to review and make recommendations for medications that had not been addressed.Results: Of the 67 medications or classes listed in the KIDs List, 47 (70.1%) of the medications are listed in our formulary and available for use. Of these 47 medications, 4 (8.5%) included warnings related to their use in pediatric patients. Of the 270 oral liquid medications reviewed, 206 (76.3%) contained at least 1 -potentially inappropriate excipient. Of the 20 commonly used IV medications, 3 (15%) contained at least 1 potentially inappropriate excipient.Conclusions: This review found that many medications listed in the KIDs List are included in our -institution's formulary and that few have warnings for pediatric patients built into the institutional electronic health record. Further review of medications in the formulary will be conducted to determine the next steps to implementing KIDs List recommendations.","PeriodicalId":37484,"journal":{"name":"Journal of Pediatric Pharmacology and Therapeutics","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10849687/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139708133","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Effectiveness of Alprostadil for Ductal Patency. 阿普前列地尔治疗导管通畅的效果

Journal of Pediatric Pharmacology and Therapeutics Pub Date : 2024-01-01 Epub Date: 2024-02-07 DOI: 10.5863/1551-6776-29.1.37

Caitlin M Gordon, Jason T Tan, Roxane R Carr

{"title":"Effectiveness of Alprostadil for Ductal Patency.","authors":"Caitlin M Gordon, Jason T Tan, Roxane R Carr","doi":"10.5863/1551-6776-29.1.37","DOIUrl":"10.5863/1551-6776-29.1.37","url":null,"abstract":"Objectives: This study aims to describe the effectiveness of low initial alprostadil dosages to maintain a patent ductus arteriosus (PDA) in infants with ductal-dependent congenital heart disease (DDCHD). Secondary objectives were to describe any adverse drug events, describe prescribing trends, describe ductus arteriosus diameter changes, and compare the safety and efficacy of very low and low initial alprostadil dosage regimens.Methods: This retrospective observational cohort study at the British Columbia's Women's and Children's Hospital neonatal intensive care unit and pediatric intensive care unit examined neonates admitted with DDCHD who received alprostadil to maintain ductal patency. Very low-dose alprostadil (less than 0.01 mcg/kg/min) versus low-dose alprostadil (equal to or greater than 0.01 mcg/kg/min) was examined. Effectiveness was defined as survival and infants not requiring a resuscitation event (cardiac arrest, cardiogenic shock, code blue, extracorporeal life support, requirement for emergent cardiac surgery, and respiratory acidosis). Adverse drug events with a Naranjo score of 3 or more were included.Results: Alprostadil was effective for 88% of patients, with no difference between the very low-dose and low-dose groups. Of the 75 patients included, 25 received very low-dose alprostadil. Adverse drug events were common (51%) with neonates in the low-dose group experiencing more apnea and pyrexia than neonates in the very low-dose group.Conclusions: Alprostadil therapy was effective in maintaining the PDA in neonates with DDCHD with low-dosage regimens. Adverse drug events were common with both dosage regimens; however, the very low dosage appeared to have less apnea and pyrexia.","PeriodicalId":37484,"journal":{"name":"Journal of Pediatric Pharmacology and Therapeutics","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10849693/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139708131","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

The Bioavailability of CHF6563, an Ethanol-Free, Sublingual Neonatal Buprenorphine Formulation: A Bridging Study Conducted in Adults. 无乙醇、舌下含服新生儿丁丙诺啡制剂 CHF6563 的生物利用度：在成人中开展的一项衔接研究。

Journal of Pediatric Pharmacology and Therapeutics Pub Date : 2024-01-01 Epub Date: 2024-02-07 DOI: 10.5863/1551-6776-29.1.49

Walter K Kraft, Irene Barneschi, Maria Bocchi, Debora Santoro, Massimo Cella

{"title":"The Bioavailability of CHF6563, an Ethanol-Free, Sublingual Neonatal Buprenorphine Formulation: A Bridging Study Conducted in Adults.","authors":"Walter K Kraft, Irene Barneschi, Maria Bocchi, Debora Santoro, Massimo Cella","doi":"10.5863/1551-6776-29.1.49","DOIUrl":"10.5863/1551-6776-29.1.49","url":null,"abstract":"Objective: Sublingual buprenorphine has demonstrated efficacy for treatment of the neonatal opioid withdrawal syndrome (NOWS), but the current formulation used in clinical practice contains 30% ethanol. Ethanol as a pharmacologically active excipient ideally should be removed from neonatal formulations. The objective of this study was to determine the relative bioavailability of a novel ethanol-free -formulation (CHF6563) compared with the commonly used ethanolic solution in a phase I, open-label, 2-period, -single-dose, crossover study in healthy adults.Methods: Eighteen adult opioid-naïve volunteers were administered one of the formulations in a randomized crossover treatment. After a 10-day washout period, subjects received the other formulation. Serial blood samples were drawn for pharmacokinetic analysis over 48 hours.Results: The geometric mean ratio (90% CIs) of the ethanol-free buprenorphine solution AUC0-last was 0.80 (0.65-0.99) and Cmax was 0.81 (0.66-0.99) compared with reference ethanolic formulation. The -ethanol-free formulation had a greater degree of intersubject variability than the ethanol-containing -reference formulation (coefficient of variation of 59% vs 31.5%, respectively, for AUC0-last).Conclusions: In an adult population, a novel ethanol-free formulation of buprenorphine containing widely used excipients demonstrated a slight decrease in bioavailability when compared with an ethanolic solution. These results will inform those seeking to develop ethanol-free pediatric drug formulations.","PeriodicalId":37484,"journal":{"name":"Journal of Pediatric Pharmacology and Therapeutics","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10849686/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139708136","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

The Pharmacy Students' Guide to Artificial Intelligence-AI. 药学专业学生人工智能指南》。

Journal of Pediatric Pharmacology and Therapeutics Pub Date : 2024-01-01 Epub Date: 2024-02-07 DOI: 10.5863/1551-6776-29.1.85

Chandler Batson, David Mara

引用次数: 0

2024 and The Journal of Pediatric Pharmacology and Therapeutics. 2024 和《儿科药理学与治疗学杂志》。

Journal of Pediatric Pharmacology and Therapeutics Pub Date : 2024-01-01 Epub Date: 2024-02-07 DOI: 10.5863/1551-6776-29.1.4

Michael D Reed

引用次数: 0

Public Interest in Montelukast Prior to and After Announcement of Black Box Warning and Associations With Adverse Event Reports. 公布黑框警告前后公众对孟鲁司特的兴趣以及与不良事件报告的关联。

Journal of Pediatric Pharmacology and Therapeutics Pub Date : 2024-01-01 Epub Date: 2024-02-07 DOI: 10.5863/1551-6776-29.1.90

Samer Abdelkader, Micah Hartwell, Amy D Hendrix-Dicken, Michelle Escala, Michelle Condren

引用次数: 0

Pharmacologic Management of Sialorrhea in Neonatal and Pediatric Patients. 新生儿和儿科患者涎泻的药物治疗。

Journal of Pediatric Pharmacology and Therapeutics Pub Date : 2024-01-01 Epub Date: 2024-02-07 DOI: 10.5863/1551-6776-29.1.6

Caitlyn V Bradford, Avery M Parman, Peter N Johnson, Jamie L Miller

{"title":"Pharmacologic Management of Sialorrhea in Neonatal and Pediatric Patients.","authors":"Caitlyn V Bradford, Avery M Parman, Peter N Johnson, Jamie L Miller","doi":"10.5863/1551-6776-29.1.6","DOIUrl":"10.5863/1551-6776-29.1.6","url":null,"abstract":"Sialorrhea, defined as an excess flow of saliva or excessive secretions, is common in patients with cerebral palsy and other neurologic disorders and is associated with clinical complications such as increased risk of local skin reactions, infections, aspiration, pneumonia, and dehydration. Upon failure of non-pharmacologic measures, clinicians have several noninvasive pharmacologic options available to manage sialorrhea. This review of the literature provides detailed descriptions of medications used, efficacy, safety, and practical considerations for use of non-injectable pharmacologic agents. The literature search included published -human studies in the English language in PubMed and Google Scholar from 1997 to 2022. Relevant citations within articles were also screened. A total of 15 studies representing 719 pediatric patients were included. Glycopyrrolate, atropine, scopolamine, and trihexyphenidyl all have a potential role for sialorrhea management in children; however, glycopyrrolate remains the most studied option with 374 (n = 52.0%) of the 719 patients included in the systematic review receiving this medication. Overall, glycopyrrolate showed similar efficacy but higher tolerability than its comparators in 2 comparative studies and is often considered the first-line agent. Patient-specific (age, route of administration) and medication-specific (dosage formulation, medication strength) considerations must be weighed when initiating a new therapy or switching to another medication upon treatment failure. Owing to the high propensity of adverse events with all agents, clinicians should consider initiating doses at the lower end of the dosage range, as previous studies have noted a dose-dependent relationship.","PeriodicalId":37484,"journal":{"name":"Journal of Pediatric Pharmacology and Therapeutics","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10849690/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139708134","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

The Past, Present, and Future of Oral Dosage Forms for Children. 儿童口服剂型的过去、现在和未来。

Journal of Pediatric Pharmacology and Therapeutics Pub Date : 2024-01-01 Epub Date: 2024-02-07 DOI: 10.5863/1551-6776-29.1.22

Rachel S Meyers

引用次数: 0

Determining Adherence to Inhaled Corticosteroids From the Epic Electronic Medical Record. 通过 Epic 电子病历确定吸入性皮质类固醇的依从性。

Journal of Pediatric Pharmacology and Therapeutics Pub Date : 2024-01-01 Epub Date: 2024-02-07 DOI: 10.5863/1551-6776-29.1.45

Ashley Galbreath, Anzeela Schentrup, Sreekala Prabhakaran, Dawn Baker, Alicia Hardy, Leslie Hendeles

{"title":"Determining Adherence to Inhaled Corticosteroids From the Epic Electronic Medical Record.","authors":"Ashley Galbreath, Anzeela Schentrup, Sreekala Prabhakaran, Dawn Baker, Alicia Hardy, Leslie Hendeles","doi":"10.5863/1551-6776-29.1.45","DOIUrl":"10.5863/1551-6776-29.1.45","url":null,"abstract":"Objective: Often we call the patient's pharmacy to obtain a refill history to assess inhaled corticosteroid (ICS) adherence. The purpose of this project was to determine the accuracy of refill histories for ICS (with or without long-acting beta agonist) listed in Epic's Medication Dispense History.Methods: We evaluated 61 patients and used data from 38 who met the following criteria: 1) under the care of the UF Pediatric Severe Asthma Clinic; 2) taking the same dose of the same ICS product for 6 months before the patient's last clinic visit; and 3) having data available from the pharmacy where the last ICS prescription was electronically sent. We called the pharmacies to obtain a verbal report of their refill record. Then, we compared the number of refills reported to the number listed in Epic's records using a Wilcoxon matched-pairs signed-ranks test.Results: Of the 293 refill dates listed in Epic, 157 were duplicates, giving a 54% error. After deleting duplicates, the mean (SD) number of refills listed in Epic was 3.6 (2.0) compared with 3.3 (2.0) in pharmacies over a period of 6 months (p < 0.0001). After removing duplicates Epic correctly reported the total number of refills for 30 of the 38 patients (78.9%). Seven of the remaining patients had more refills listed in Epic while 1 patient had more refills dispensed.Conclusion: This study indicates that our version of Epic over-reports refills thus limiting assessment of adherence. In contrast, absence of refills in Epic is a clear indication of poor adherence.","PeriodicalId":37484,"journal":{"name":"Journal of Pediatric Pharmacology and Therapeutics","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10849692/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139708128","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0